Cue Biopharma, Inc.
CUE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645460
In the last 90 days, Cue Biopharma, Inc. insiders filed 0 open-market purchases and 3 sales; 50 institutions reported holding it in 13F filings for Q2 2026, worth $52.2M in total; no superinvestor holds it.
Holders of 5% or more of CUE
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cue Biopharma, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Bleichroeder LP | 13G/A | 9.99%6.13M shares | 0.00 ppfrom 9.99% | Oct 7, 20242 filings | Mar 21, 2025 | SEC |
| Driehaus Capital Management LLC | 13G | 6.96%292.1K shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Lin Shao-Lee | 13D | 6.20%467.2K shares | New | Aug 21, 20261 filing | Aug 21, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
14 Schedule 13D and 13G filings on Cue Biopharma, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 20264:55 PM ET | Lin Shao-Lee | 13D | 6.20%467.2K shares | New | May 3, 2026 | SEC |
| Aug 14, 20267:37 AM ET | Driehaus Capital Management LLC | 13G | 6.96%292.1K shares | New | Jun 30, 2026 | SEC |
| May 16, 20254:01 PM ET | Strome Mark Eand 3 others | 13G/A | 4.99%2.17M shares | –Below 5% | Nov 14, 2022 | SEC |
| Mar 21, 20257:14 PM ET | Bleichroeder LPand 2 others | 13G/A | 9.99%6.13M shares | 0.00 ppfrom 9.99% | Mar 19, 2025 | SEC |
| Feb 14, 20255:00 PM ET | Slate Path Capital LPand 1 other | 13G/A | 1.40%918.8K shares | –Below 5% | Dec 31, 2024 | SEC |
| Oct 7, 20245:07 PM ET | Bleichroeder LPand 1 other | 13G/A | 9.99%6.13M shares | – | Sep 30, 2024 | SEC |
| Feb 14, 2023 | Slate Path Capital LP | 13GOld format | – | – | – | SEC |
| Feb 3, 2023 | State Street Corp | 13G/AOld format | – | – | – | SEC |
| Dec 2, 2022 | Nantahala Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Nov 18, 2022 | Slate Path Capital LP | 13GOld format | – | New | – | SEC |
| Jul 8, 20224:57 PM ET | BlackRock Inc. | 13GOld format | – | – | – | SEC |
| Feb 14, 2022 | Corriente Advisors, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Nantahala Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | State Street Corp | 13GOld format | – | New | – | SEC |
| Feb 3, 20224:41 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Corriente Advisors, LLC | 13GOld format | – | New | – | SEC |
| Feb 12, 2021 | Nantahala Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Avoro Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Jan 29, 20219:56 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Cue Biopharma, Inc. shares.
No Form 144 notices for Cue Biopharma, Inc. are on file.